Merck & Co., Inc. (NYSE:MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a deal ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...

The first half of this year been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , ...

With updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.

Merck’s combo of KEYTRUDA and Trodelvy reduces disease progression or death risk by 35% in tough-to-treat breast cancer.

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating ...